Product Description: Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer[1][3]. Cidofovir also has anti-orthopoxvirus and anti-variola activities[4].
Applications: COVID-19-anti-virus
Formula: C8H14N3O6P
References: [1]David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403./[2] M Bray, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9./[3]Simona Catalani, et al. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir. Toxicol In Vitro. 2017 Jun;41:49-55./[4]Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23.
CAS Number: 113852-37-2
Molecular Weight: 279.19
Compound Purity: 99.74
Research Area: Infection; Cancer
Solubility: DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C)/H2O : 3.33 mg/mL (ultrasonic)
Target: Apoptosis;CMV;DNA/RNA Synthesis;Endogenous Metabolite;Orthopoxvirus